卵巢恶性肿瘤风险模型和哥本哈根指数在卵巢良恶性肿瘤鉴别中的价值分析

Significance of ovarian malignancy risk model and copenhagen index in differentiating benign and malignant ovarian tumors

目的探讨卵巢恶性肿瘤风险模型(ROMA)和哥本哈根指数(CPH-I)在鉴别卵巢良恶性肿瘤中的价值。方法选取2013年2月至2018年1月间陕西省榆林市榆阳区妇幼保健院收治的120例卵巢肿瘤患者进行回顾性研究,将60例卵巢癌患者纳入癌变组,60例良性卵巢肿瘤患者纳入瘤变组,同期选取60例健康人纳入正常组,检测所有入选者的血清人附睾分泌蛋白(HE4)和糖类抗原125(CA125)的水平,计算ROMA和CPH-I值,判断诊断效果。结果癌变组的HE4和CA125水平均高于瘤变组与正常组,差异有统计学意义(P<0.05)。瘤变组与正常组间比较,差异无统计学意义(P>0.05)。癌变组的ROMA和CPH-I值都高于瘤变组与正常组,瘤变组的ROMA和CPH-I值也高于正常组,差异均有统计学意义(均P<0.05)。HE4、CA125、ROMA和CPH-I鉴别诊断卵巢癌的敏感度分别为81.7%、73.3%、95.0%和100.0%,差异有统计学意义(P<0.05),而特异度分别为88.3%、85.0%、81.7%和85.8%,差异无统计学意义(P>0.05)。结论 ROMA和CPH-I鉴别诊断卵巢良恶性肿瘤均优于传统的肿瘤标志物CA125和HE4,是较为客观的风险评估工具,有很好的临床应用价值。

Objective To evaluate the values of ovarian malignancy risk model （ROMA） and co- penhagen index （CPH-I） in differentiating benign and malignant ovarian tumors. Methods A totsl of 120 patients with ovarian tumors treated at Yuyang District Maternal and Child Health Care Hospital from Febru- ary 2013 to January 2018 were retrospective studied. Among them, 60 patients with ovarian cancer were in- cluded in cancerous group, 60 patients with benign ovarian tumors were included in tumor group and 60 healthy individuals were involved in the normal group. The serum levels of human epididymal secretory pro- tein （HE4） and carbohydrate antigen 125 （CA125） were detected, and the values of ROMA and CPH-I were calculated. Results The levels of HE4 and CA125 were higher in the cancerous group than in the tumor and normal groups （ all P 〈 0. 05 ）. There was no significant difference in the level of HFA and CA125 between tumor group and normal group （P 〉 0. 05 ）. The ROMA and CPH-I were higher in the cancerous group than in the tumor group and normal group （ all P 〈 0. 05 ）. The ROMA and CPH-Ⅰ were higher in the tumor group than in the normal group （all P 〈 0. 05）. The sensitivity of HE4, CA125, ROMA and CPH-I in the differential diagnosis of ovarian cancer was 81.7% , 73.3% , 95.0% and 100.0% respectively （ all P 〈0. 05） , and the specificity was 88.3%, 85.0% , 81.7% and 85.8%, respectively （P 〉0. 05）. Con-clusion ROMA and CPH-I in the differential diagnosis of benign and malignant ovarian tumors is superior to the traditional tumor markers CA125 and HE and they were objective risk assessment tools and have good clinical application values.